TLX trades 61.8% below Wall Street's consensus target of $19.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TLX achieves its forward estimates and maintains a stable P/E multiple of 254.7x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Telix Pharmaceuticals Limited (TLX) has a Wall Street consensus price target of $19.00, based on estimates from 5 covering analysts. With the stock currently trading at $11.74, this represents a potential upside of +61.8%. The company has a market capitalization of $3.98B.
Analyst price targets range from a low of $17.00 to a high of $20.00, representing a 16% spread in expectations. The median target of $20.00 differs from the mean, suggesting potential outlier estimates. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TLX trades at a trailing P/E of -537.8x and forward P/E of 254.7x. Analysts expect EPS to grow -60.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $20.49, with bear and bull scenarios of $12.91 and $27.00 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EXELExelixis, Inc. | $14.5B | $57.08 | $50.00 | -12.4% | Hold | 16.2x | 33 |
RNWReNew Energy Global Plc | $2.2B | $6.01 | $6.39 | +6.3% | Buy | 0.4x | 6 |
AGENAgenus Inc. | $146M | $3.50 | $7.33 | +109.4% | Buy | 4.5x | 11 |
LNTHLantheus Holdings, Inc. | $6.7B | $103.41 | $108.50 | +4.9% | Buy | 19.3x | 17 |
NVSNovartis AG | $299.6B | $157.03 | $170.00 | +8.3% | Hold | 18.0x | 25 |
BMYBristol-Myers Squibb Company | $118.4B | $57.97 | $62.60 | +8.0% | Hold | 9.2x | 41 |
PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
GEGE Aerospace | $383.4B | $366.98 | $393.00 | +7.1% | Buy | 48.6x | 34 |
GEHCGE HealthCare Technologies Inc. | $29.5B | $64.89 | $81.00 | +24.8% | Buy | 13.3x | 18 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
Quick answers to the most common questions about buying TLX stock.
The consensus Wall Street price target for TLX is $19, representing 61.8% upside from the current price of $11.74. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TLX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies 61.8% upside from current levels.
At a forward P/E of 254.6638x, TLX trades at a premium valuation. The consensus price target of $19 (61.8% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $20 for TLX, while the most conservative target is $17. The consensus of $19 represents the median expectation. Our quantitative valuation model projects a bull case target of $27 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TLX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TLX stock forecast based on 5 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $17 (bear case) to $20 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $20, with bear/bull scenarios of $13/$27.
Our quantitative valuation model calculates TLX's fair value at $20 (base case), with a bear case of $13 and bull case of $27. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
TLX trades at a forward P/E ratio of 254.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on TLX, with a "Buy" consensus rating and $19 price target (61.8% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TLX analyst price targets range from $17 to $20, a 16% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground. Our model's $13-$27 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.